BioMimetix JV
Manufacturing · Colorado, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
5340 S Quebec St Ste 345N, Greenwood Vil...Phone Number
(720) 613-4806Website
www.biomimetixpharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About BioMimetix JV
BioMimetix is a pioneering biotechnology firm established in 2013, focused on developing a novel drug class of redox-active metalloporphyrins for cancer treatment. Their flagship compound, BMX-001, has shown clinical efficacy in multiple oncology indications and is designed to enhance tumor killing while protecting healthy tissue. The company is preparing for a Phase 3 pivotal trial in high-grade glioma and has received FDA Breakthrough Therapy designation. BioMimetix aims to transform chemoradiation across various cancer types with its innovative platform.Explore more
BioMimetix JV Org Chart
SG
Vice President, Drug Safety, Regulatory Affai...
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BioMimetix JV your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if BioMimetix JV has recently received funding, and reach out quickly before it becomes old news!
BioMimetix JV, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if BioMimetix JV had a recent Job posting/layoffs
Check out if BioMimetix JV is spiking on competitors!
Product Launch: Get notified when BioMimetix JV launches new products
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once BioMimetix JV has new funding data
Congratulate Masked Content for being promoted to Masked Content at BioMimetix JV
Earning: See what the market has to say on BioMimetix JV recently announced quarterly report
Recommended Actions
Find VP level buyers at BioMimetix JV
Find 2 more new buyers
Compare Similar Companies to BioMimetix JV
Compare insights from companies similar to BioMimetix JV, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BioMimetix JV is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BioMimetix JV is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BioMimetix JV.
BioMimetix JV Tech Stack
A closer look at the technologies used by BioMimetix JV
See more technologies
BioMimetix JV News & Media
BioMimetix Announces Acceptance of Late-Breaking Abstract and Oral Presentation of BMX-001 Clinical Data at the 2023 Society for Neuro-Oncology Annual Meeting
GREENWOOD VILLAGE, Colo.--(BUSINESS WIRE)--BioMimetix JV, LLC, a clinical-stage biotechnology company developing metalloporphyrins, a novel drug class for the treatment of cancer patients, today announced that data from its Phase 2 study of lead candidate, BMX-001, for the treatment of high-grade glioma (HGG), has been selected as a late breaking oral presentation at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting taking place on November 15-19, 2023 in Vancouver, Canada. In line withHigh-grade Glioma Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Companies to Watch Out - BioMimetix, Bayer, MedImmune, DNAtrix, Chimerix, Bristol-Myers Squibb, Laminar, Immunomic, Inovio
The dynamics of the high-grade glioma market are anticipated to change in the coming years owing to the positive outcomes of the emerging pipeline candidates during the developmental stage by key players. LAS VEGAS, Oct. 25, 2023 /PRNewswire/ -- DelveInsight's High-grade Glioma Market...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BioMimetix JV
Sign Up For FreeTo access detailed company insights
BioMimetix is a pioneering biotechnology firm established in 2013, focused on developing a novel drug class of redox-active metalloporphyrins for cancer treatment. Their flagship compound, BMX-001, has shown clinical efficacy in multiple oncology indications and is designed to enhance tumor killing while protecting healthy tissue. The company is pr... Read More
